A/HRC/17/2 6. Takes note of the report of the Special Rapporteur on the expert consultation on access to medicines as a fundamental component of the right of everyone to the highest attainable standard of physical and mental health, held on 11 October 2010;14 7. Encourages States: (a) To implement or, where they do not exist, to establish national health frameworks that ensure access for all, without discrimination, to medicines that are affordable, safe, effective and of good quality; (b) To raise awareness about the responsible use of medicines, including through the wide dissemination of information in that regard, taking into account the potential risks to health; (c) To ensure that investment, industrial or other policies promote development and access to medicines, in particular their affordability; (d) To promote the transparent and informed participation of relevant stakeholders, as appropriate, in formulating national medicines policies and programmes; (e) To strengthen or, where they do not exist, to establish national monitoring and accountability mechanisms for policies relating to access to medicines; (f) To ensure that procurement practices and procedures for medicines are transparent, fair and competitive; (g) To promote access to medicines for all, including through the use, to the full, of the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights, which provide flexibility for that purpose, recognizing that the protection of intellectual property is important for the development of new medicines as well as the concerns about its effects on prices; (h) To foster the development of technology and the voluntary transfer of technology to developing countries on mutually agreed terms aligned with national priorities; (i) To apply measures and procedures for enforcing intellectual property rights in such a manner as to avoid creating barriers to the legitimate trade of affordable, safe, effective and good-quality medicines, and to provide for safeguards against the abuse of such measures and procedures; (j) To strengthen or, where they do not exist, to establish national health regulatory systems that ensure the quality, safety and efficacy of medicines; (k) To promote the improvement of health infrastructures necessary for access to affordable, safe, effective and good-quality medicines, such as storage and distribution systems; 8. Recognizes the innovative funding mechanisms that contribute to the availability of vaccines and medicines in developing countries, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, the GAVI Alliance and the International Drug Purchase Facility, UNITAID, and calls upon all States, United Nations programmes and agencies, in particular the World Health Organization, and relevant intergovernmental organizations, within their respective mandates, and encourages relevant stakeholders, including pharmaceutical companies, to further collaborate to enable equitable access to 14 40 A/HRC/17/43. GE.12-13630